combretastatin and fosbretabulin
combretastatin has been researched along with fosbretabulin in 17 studies
Research
Studies (17)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (23.53) | 29.6817 |
| 2010's | 9 (52.94) | 24.3611 |
| 2020's | 4 (23.53) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Hill, SA; Kanthou, C; Parkins, CS; Tozer, GM | 1 |
| Anthoney, DA; Bibby, MC; Cooper, PA; Kirwan, IG; Lippert, JW; Loadman, PM; Pettit, GR; Shnyder, SD; Swaine, DJ | 1 |
| Beltrami, L; Busacca, S; Genazzani, AA; Imovilli, D; Massarotti, A; Miglio, G; Pagliai, F; Pirali, T; Sorba, G; Tron, GC; Verotta, L | 1 |
| Burchill, SA; Dalal, S | 1 |
| Hogan, F; Minardi, MD; Pettit, GR; Price, PM | 1 |
| Hua, R; Li, J; Liu, T | 1 |
| Babu, B; Brockway, O; Dandavati, A; Lee, M; Mooberry, SL; Satam, V; Sjoholm, R; Tzou, S; Westbrook, C; Zeller, M | 1 |
| Babu, B; Bandi, RK; Behera, AK; Brockway, O; Lee, M; Mishra, BK; Mooberry, SL; Pati, H; Satam, V; Tzou, S; Westbrook, C; Zeller, M | 1 |
| Bisby, RH; Botchway, SW; Hadfield, JA; McGown, AT; Parker, AW; Scherer, KM | 1 |
| Chaplin, DJ; Garner, CM; Ghatak, A; Hadimani, MB; Hall, JJ; Hamel, E; Kessler, RJ; Liu, L; Lopez, R; Macdonough, MT; Mason, RP; Nguyen, BL; Pettit, GR; Pinney, KG; Shirali, AR; Sriram, M; Strecker, TE; Trawick, ML | 1 |
| Lipeeva, AV; Pokrovsky, AG; Pokrovsky, MA; Shakirov, MM; Shults, EE | 1 |
| Bao, K; Guan, Q; Guo, D; Jiang, M; Liu, C; Wu, Y; Xu, J; Yang, F; Zhang, W | 1 |
| Aoshima, K; Hoshino, Y; Izumi, Y; Takagi, S | 1 |
| Kankala, RK; Kankala, S; Nerella, S; Paidakula, S | 1 |
| Kozhevnikova, AA; Mikhaevich, EI; Salnikova, DI; Scherbakov, A; Shirinian, VZ; Yadykov, AV; Zakharov, AV | 1 |
| Abourehab, MAS; Beshay, BY; Elbastawesy, MAI; Masoud, RE; Moustafa, AMY; Zakaria, MY; Zaki, I | 1 |
| Chen, Y; Huang, X; Liu, Z; Wang, H; Zhang, B; Zhang, H; Zhong, W | 1 |
Reviews
2 review(s) available for combretastatin and fosbretabulin
| Article | Year |
|---|---|
The biology of the combretastatins as tumour vascular targeting agents.
Topics: Animals; Antineoplastic Agents, Phytogenic; Bibenzyls; Endothelium, Vascular; Humans; Neoplasms; Neovascularization, Pathologic; Stilbenes | 2002 |
Recent Trends in Tubulin-Binding Combretastatin A-4 Analogs for Anticancer Drug Development.
Topics: Antineoplastic Agents; Bibenzyls; Cell Line, Tumor; Cell Proliferation; Drug Design; Humans; Neoplasms; Stilbenes; Structure-Activity Relationship; Tubulin; Tubulin Modulators | 2022 |
Other Studies
15 other study(ies) available for combretastatin and fosbretabulin
| Article | Year |
|---|---|
Comparative preclinical pharmacokinetic and metabolic studies of the combretastatin prodrugs combretastatin A4 phosphate and A1 phosphate.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Area Under Curve; Bibenzyls; Calibration; Cell Line, Tumor; Chromatography; Chromatography, High Pressure Liquid; Coloring Agents; Female; Humans; Inhibitory Concentration 50; Mass Spectrometry; Mice; Models, Chemical; Phosphorylation; Prodrugs; Stilbenes; Tetrazolium Salts; Thiazoles; Time Factors | 2004 |
Synthesis and cytotoxic evaluation of combretafurans, potential scaffolds for dual-action antitumoral agents.
Topics: Anisoles; Antineoplastic Agents; Bibenzyls; Cell Death; Cell Line, Tumor; Drug Screening Assays, Antitumor; Furans; Humans; Molecular Structure; Neuroblastoma; Stilbenes; Structure-Activity Relationship; Tubulin | 2006 |
Preclinical evaluation of vascular-disrupting agents in Ewing's sarcoma family of tumours.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bibenzyls; Bone Neoplasms; Cell Proliferation; Diphosphates; Disease Models, Animal; Doxorubicin; Drug Evaluation, Preclinical; Mice; Mice, Nude; Necrosis; Neoplasm Transplantation; Neovascularization, Pathologic; Sarcoma, Ewing; Stilbenes | 2009 |
An efficient synthetic strategy for obtaining 4-methoxy carbon isotope labeled combretastatin A-4 phosphate and other Z-combretastatins.
Topics: Bibenzyls; Isotope Labeling; Molecular Structure; Positron-Emission Tomography; Stereoisomerism; Stilbenes | 2010 |
Highly chemo- and stereoselective palladium-catalyzed transfer semihydrogenation of internal alkynes affording cis-alkenes.
Topics: Alkenes; Alkynes; Bibenzyls; Catalysis; Dimethylformamide; Hydrogen; Hydrogenation; Hydroxides; Molecular Structure; Palladium; Potassium Compounds; Stereoisomerism; Stilbenes | 2010 |
A novel class of trans-methylpyrazoline analogs of combretastatins: synthesis and in-vitro biological testing.
Topics: Animals; Antineoplastic Agents, Phytogenic; Bibenzyls; Cell Line, Tumor; Cell Survival; Crystallography, X-Ray; Drug Screening Assays, Antitumor; Humans; Inhibitory Concentration 50; Leukemia L1210; Melanoma, Experimental; Mice; Microtubules; Molecular Docking Simulation; Pyrazoles; Stilbenes; Structure-Activity Relationship; Tubulin Modulators | 2011 |
Design, synthesis, and cytotoxicity of novel 3-arylidenones derived from alicyclic ketones.
Topics: Animals; Antineoplastic Agents; Bibenzyls; Cell Line, Tumor; Cell Survival; Chalcones; Drug Design; Humans; Ketones; Mice; Models, Molecular; Neoplasms; Stilbenes; Structure-Activity Relationship; Tubulin Modulators | 2011 |
Fluorescence lifetime imaging of E-combretastatin uptake and distribution in live mammalian cells.
Topics: Animals; Bibenzyls; CHO Cells; Cricetinae; HeLa Cells; Humans; Microscopy, Fluorescence, Multiphoton; Stilbenes | 2012 |
Synthesis of a 2-aryl-3-aroyl indole salt (OXi8007) resembling combretastatin A-4 with application as a vascular disrupting agent.
Topics: Animals; Antineoplastic Agents; Bibenzyls; Colchicine; Drug Screening Assays, Antitumor; Humans; Indoles; Inhibitory Concentration 50; Male; Mice; Molecular Structure; Organophosphates; Prodrugs; Prostatic Neoplasms; Stilbenes; Structure-Activity Relationship; Tubulin | 2013 |
Synthesis and cytotoxic activity of a new group of heterocyclic analogues of the combretastatins.
Topics: Antineoplastic Agents, Phytogenic; Bibenzyls; Cell Line, Tumor; Coumarins; Drug Screening Assays, Antitumor; Ficusin; Furocoumarins; Humans; Molecular Structure; Neoplasms; Stilbenes; Structure-Activity Relationship; Tubulin Modulators | 2014 |
Synthesis and biological evaluation of novel 3,4-diaryl-1,2,5-selenadiazol analogues of combretastatin A-4.
Topics: Antineoplastic Agents, Phytogenic; Bibenzyls; Cell Cycle; Cell Proliferation; Drug Screening Assays, Antitumor; Flow Cytometry; Fluorescent Antibody Technique; Heterocyclic Compounds; Humans; Models, Molecular; Molecular Structure; Neoplasms; Selenium; Stilbenes; Structure-Activity Relationship; Tumor Cells, Cultured | 2014 |
Effects of combretastatin A-4 phosphate on canine normal and tumor tissue-derived endothelial cells.
Topics: Animals; Bibenzyls; Cells, Cultured; Dogs; Endothelial Cells; Endothelium, Vascular; Humans; Neoplasms; Neovascularization, Pathologic; Phosphates; Stilbenes | 2017 |
Photostability and Antiproliferative Activity of Furan Analogues of Combretastatin A-4.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Furans; Humans; Molecular Structure; Pharmaceutical Preparations; Quality of Life; Structure-Activity Relationship | 2022 |
Design and synthesis of new trimethoxylphenyl-linked combretastatin analogues loaded on diamond nanoparticles as a panel for ameliorated solubility and antiproliferative activity.
Topics: Amides; Antineoplastic Agents; Bibenzyls; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Molecular Structure; Nanoparticles; Solubility; Stilbenes; Structure-Activity Relationship; Tubulin; Tubulin Modulators | 2022 |
Novel combretastatin A-4 derivative containing aminophosphonates as dual inhibitors of tubulin and matrix metalloproteinases for lung cancer treatment.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Lung Neoplasms; Matrix Metalloproteinases; Tubulin; Tubulin Modulators | 2022 |